Target Name: CDCA8
NCBI ID: G55143
Review Report on CDCA8 Target / Biomarker Content of Review Report on CDCA8 Target / Biomarker
CDCA8
Other Name(s): Cell division cycle-associated protein 8 | cell division cycle-associated protein 8 | Dasra B | BOR | dasra-B | Borealin | DasraB | CDCA8 variant 2 | pluripotent embryonic stem cell-related gene 3 protein | cell division cycle associated 8 | Cell division cycle associated 8, transcript variant 1 | hDasra-B | BOREA_HUMAN | BOREALIN | Dasra-B | Pluripotent embryonic stem cell-related gene 3 protein | CDCA8 variant 1 | MESRGP | Cell division cycle associated 8, transcript variant 2

CDCA8: A Promising Drug Target and Biomarker for Cell division Cycle-Associated Protein 8

CDCA8, or Cell Division Cycle-Associated Protein 8, is a protein that plays a critical role in the cell division cycle. It is a key regulator of the G1 phase, which is a critical phase of cell growth and development. CDCA8 helps ensure that cells enter the G2 phase, where they prepare for cell division. In addition to its role in regulating the cell division cycle, CDCA8 has also been shown to play a significant role in cancer progression.

CDCA8 is a protein that is expressed in a wide range of tissues and cells, including muscle, pancreatic, and ovarian cells. It is also expressed in various types of cancer, including breast, lung, and colorectal cancer. This makes CDCA8 an attractive drug target for cancer researchers, as it could potentially be used to treat a wide range of cancer types.

CDCA8 as a Drug Target

One of the main ways that CDCA8 could be used as a drug target is by inhibiting its activity. Researchers have shown that CDCA8 is involved in a variety of cellular processes, including cell division, cell signaling, and cell adhesion. They have also shown that CDCA8 interacts with several other proteins, including the transcription factor, p53.

In addition to its role in cell signaling, CDCA8 has also been shown to play a significant role in the regulation of cell division. It helps ensure that cells enter the G2 phase, where they prepare for cell division. This is important for the regulation of cell growth and development, as well as for the prevention of cancer.

CDCA8 as a Biomarker

CDCA8 has also been shown to be a useful biomarker for cancer. Its expression has been shown to be associated with the development of various types of cancer, including breast, lung, and colorectal cancer. This makes CDCA8 a potential biomarker for these cancers, and could potentially be used for the diagnosis and monitoring of these diseases.

In addition to its potential as a drug target, CDCA8 has also been shown to be a potential biomarker for cancer. Its expression has been shown to be associated with the development of various types of cancer, including breast, lung, and colorectal cancer. This makes CDCA8 a potential biomarker for these diseases, and could potentially be used for the diagnosis and monitoring of these conditions.

Conclusion

CDCA8 is a protein that plays a critical role in the cell division cycle. It is a key regulator of the G1 phase, and has also been shown to play a significant role in cancer progression. As a result, CDCA8 is an attractive drug target for cancer researchers, and could potentially be used to treat a wide range of cancer types. In addition to its potential as a drug target, CDCA8 has also been shown to be a potential biomarker for cancer. Further research is needed to fully understand its role in these processes, and to develop effective treatments.

Protein Name: Cell Division Cycle Associated 8

Functions: Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Major effector of the TTK kinase in the control of attachment-error-correction and chromosome alignment

The "CDCA8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDCA8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN